Brainstorm Cell Therapeutics Inc. financial data

Symbol
BCLI on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
1325 Avenue Of Americas, 28 Th Floor, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
GOLDEN HAND RESOURCES INC (to 11/22/2004), WIZBANG TECHNOLOGIES INC (to 8/8/2003)
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 25 % -5.6%
Debt-to-equity -176 % +40%
Return On Equity 285 % -38.7%
Return On Assets -373 % -55.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 5.7M shares -88.4%
Common Stock, Shares, Outstanding 5.31M shares -88.3%
Entity Public Float 78.9M USD -34%
Common Stock, Value, Issued 14K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 5.31M shares +80%
Weighted Average Number of Shares Outstanding, Diluted 5.31M shares +80%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 4.63M USD -59.8%
General and Administrative Expense 8.68M USD -13.6%
Operating Income (Loss) -13.3M USD +38.2%
Net Income (Loss) Attributable to Parent -14.2M USD +14.5%
Earnings Per Share, Basic -0.28 USD/shares +67.1%
Earnings Per Share, Diluted -0.28 USD/shares +67.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 168K USD -86.3%
Assets, Current 364K USD -76.3%
Property, Plant and Equipment, Net 499K USD -33.6%
Operating Lease, Right-of-Use Asset 959K USD -71.5%
Other Assets, Noncurrent 1.66M USD -59.9%
Assets 2.03M USD -64.4%
Accounts Payable, Current 4.6M USD +17.2%
Employee-related Liabilities, Current 1.04M USD
Accrued Liabilities, Current 865K USD +1273%
Liabilities, Current 7.08M USD +12%
Operating Lease, Liability, Noncurrent 271K USD -82.9%
Liabilities 8.08M USD -2.2%
Retained Earnings (Accumulated Deficit) -224M USD -6.79%
Stockholders' Equity Attributable to Parent -6.06M USD -135%
Liabilities and Equity 2.03M USD -64.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -11.3M USD +48.1%
Net Cash Provided by (Used in) Financing Activities 17.4M USD -17.5%
Net Cash Provided by (Used in) Investing Activities 2.19M USD +120%
Common Stock, Shares Authorized 250M shares +150%
Common Stock, Shares, Issued 5.31M shares -88.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -873K USD +70.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 349K USD -71.4%
Deferred Tax Assets, Valuation Allowance 50.8M USD +19%
Deferred Tax Assets, Gross 50.8M USD +19%
Operating Lease, Liability 841K USD -70.9%
Depreciation 253K USD -5.95%
Payments to Acquire Property, Plant, and Equipment 18K USD +1700%
Lessee, Operating Lease, Liability, to be Paid 897K USD -71%
Property, Plant and Equipment, Gross 3.45M USD +0.53%
Operating Lease, Liability, Current 570K USD -56.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two 185K USD -86.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 563K USD +68.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure +29.6%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 56K USD -72.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 189K USD -86%
Lessee, Operating Lease, Liability, to be Paid, Year Four 179K USD -7.25%
Operating Lease, Payments 166K USD -57%